COMP <GO>
ICFI vs ASTH // ALTMAN Z-SCORE & DEBT/EQUITY
ICF International Inc. (NASDAQ) VS. Astrana Health Inc. (NASDAQ) • 15-METRIC TALLY: ICFI 10
— ASTH 2
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ICFI
LAST: $95.84 (+1.25%) • MKT CAP: $1.72B
balance-sheet
2.87
LAST: $36.62 (-0.14%) • MKT CAP: $1.82B
balance-sheet
2.54
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICFI VS. ASTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICFI | ASTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 37.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.10% | 4.60% | +3.50 | ICFI | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.5x | 27.3x | -12.80 | ICFI | /valuation <GO> |
| Free Cash Flow Yield | 8.25% | 5.75% | +2.50 | ICFI | /fcf-yield <GO> |
| Operating Margin | 7.80% | 2.50% | +5.30 | ICFI | /operating-margins <GO> |
| Net Profit Margin | 4.90% | 0.80% | +4.10 | ICFI | /net-margins <GO> |
| Revenue Growth (YoY) | -7.30% | 56.40% | -63.70 | ASTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.60% | 0.43% | +0.17 | ICFI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.87 | 2.54 | +0.33 | ICFI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | ICFI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.4 | 47.3 | +24.10 | ICFI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 63.6x | -46.20 | ICFI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.72B | $1.82B | -$97.7M | ASTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICFI REV | ASTH REV | ICFI GROSS % | ASTH GROSS % | ICFI FCF | ASTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.87B | $3.18B | 37.2% | — | $141.9M | $104.5M |
| FY 2024 | $2.02B | $2.03B | 36.5% | — | $171.5M | $44.2M |
| FY 2023 | $1.96B | $1.39B | — | — | $152.4M | $68.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICFI // BETA —
ASTH // BETA —